JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Targeting the JAK2/STAT5 pathway showed effective reductions in viability, colony output, and proliferation of CML CD34+ cells in vitro as well as the engraftment of CML CD34+ cells in vivo.